U. S. NIH to finance Samjin viral new compound.

Published: 2006-11-27 06:57:00

Updated: 2006-11-27 06:57:00

A new anti-viral agent developed by Samjin for the treatment of HIV, an AIDS virus, has been found of its excellent efficacy, and now Samjin may receive a financial support from the U. S. NIH for the development of an innovative topical cocktail therapy.

In close association with ImQuest, a U...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK